Literature DB >> 1455904

Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

K M Hughes1, J C Lang, R Lazare, D Gordon, S L Stanton, J Malone-Lee, M Geraint.   

Abstract

1. A quantitative h.p.l.c. plasma assay for oxybutynin (OB) and its active metabolite, N-desethyl oxybutynin (DEOB) is described. The method is linear with coefficients of variation ranging between 4 and 11.8% for OB and 4.6-9.1% for DEOB over the typical concentration range measured. Minimum detectable levels were 0.5 and 5 ng/ml for OB and DEOB respectively from a 2 ml sample. 2. Pharmacokinetic parameters were obtained after a single oral dose of OB and after administration two or three times daily to frail elderly and elderly volunteer groups respectively. Single dose results were also compared with data from young healthy volunteers. 3. There was a wide range in peak blood levels and high levels of parent drug were matched by high DEOB metabolite levels. Plasma levels on repeated administration were as would be predicted from the single dose kinetics. 4. Area under the plasma time course curve for DEOB metabolite was less than or equal to 5 than that of the parent drug. 5. A trend of increasing peak plasma levels and bioavailability was observed with increasing age and frailty, with the differences more apparent between the active elderly and frail elderly groups than between the active elderly and young volunteers. 6. Results indicate that for frail elderly patients a lower initial starting dose of 2.5 mg OB given two or three times a day may provide adequate therapeutic blood levels of the drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455904     DOI: 10.3109/00498259209053145

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  35 in total

1.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

Review 2.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 3.  Update on overactive bladder: pharmacologic approaches on the horizon.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

Review 4.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

Review 5.  Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.

Authors:  Roger Dmochowski
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

7.  Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers.

Authors:  A Pietzko; W Dimpfel; U Schwantes; P Topfmeier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.

Authors:  Gary G Kay; David R Staskin; Scott MacDiarmid; Marilyn McIlwain; Naomi V Dahl
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

Review 9.  A benefit-risk assessment of extended-release oxybutynin.

Authors:  Martin C Michel
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 10.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.